Salesforce’s $1.6 Billion VA Win Puts a Spotlight on the Widest Analyst-Consensus Gap in Tech
Published on 07/26/2026 at 06:22 | Redaktion boerse-global.de
The software giant’s stock closed Friday at €144.26, up 4.6% on the session, yet that single-day pop barely registers against a 36.38% annual decline that makes Salesforce one of the worst performers in the Dow Jones Industrial Average. At 38.13% below its 52-week high of €233.15, the equity is pricing in a narrative that stands in stark opposition to what the sell-side sees coming.
That gap is now unusually large. The average analyst price target sits at €212.48, implying upside of roughly 47% from Friday’s close. Such a chasm between where the stock trades and where analysts think it should trade rarely emerges by accident. It signals that the market is discounting a scenario — either a slowdown in enterprise software spending or outright disruption from generative AI — that the analyst community has not yet embraced.
The VA Deal That Should Have Changed the Conversation
The U.S. Department of Veterans Affairs signed a one-year “Agentic Enterprise License Agreement” with Salesforce, carrying an option for two renewals and a total value of $1.6 billion. The contract aims to deploy autonomous AI agents to modernize healthcare delivery for 17 million veterans. This is not a pilot or a proof-of-concept. It is a production-scale deployment in one of the most sensitive environments imaginable.
Internally, the numbers back up the thesis. Salesforce’s annualized recurring revenue from its Agentforce platform surged 205% in the most recent quarter to $1.2 billion. Earnings per share came in at $3.88, well ahead of the $3.13 consensus estimate, while revenue reached $11.13 billion. The company has also been active on the buyback front, retiring 103 million shares from a $25 billion repurchase program — a clear signal that management views the current price as undervalued.
Should investors sell immediately? Or is it worth buying Salesforce?
Yet the stock barely budged on the VA announcement. That pattern — good news failing to catalyze a sustained rally — has become a hallmark of Salesforce trading in recent months. New government contracts, including defense-sector deals, have similarly failed to alter the trajectory.
Wall Street’s Civil War Over AI Risk
The analyst community is openly divided, and that division itself is telling. Morgan Stanley downgraded Salesforce from Overweight to Equal Weight, a notable shift from one of the most influential firms on the Street. KeyBanc and Phillip Securities followed suit, with Phillip cutting its price target sharply. Those downgrades marked a clear reversal from the more bullish calls issued in early summer.
But the bearish camp does not have the floor to itself. Guggenheim upgraded the stock to Buy just weeks earlier, arguing that the market has overestimated the AI risk to Salesforce’s core business. The result is a rare spectacle: a string of bullish and bearish calls within days of each other, leaving institutional investors without a clear consensus on how to price the company’s AI transformation.
The uncertainty is feeding directly into volatility. Salesforce’s 30-day annualized volatility stands at 42.12%, an elevated reading even for a beaten-down growth stock.
The Core Question: Does AI Eat Its Own?
The fundamental debate boils down to a single question: Is generative AI a growth driver for Salesforce or a threat to its legacy seat-based licensing model? The prevailing market narrative holds that AI budgets are cannibalizing traditional software spending, putting Salesforce in the same crosshairs as Workday and ServiceNow.
That concern is not baseless, but it may be overwrought. The market’s reaction function has become so uniformly negative that even unambiguous good news — like the VA deal — fails to move the needle. That pattern suggests panic selling rather than a careful fundamental reassessment.
Salesforce is not standing still. The company is actively acquiring its way into the next software generation, most recently with plans to buy Fin, a provider of agent-based AI customer-support software designed to strengthen the Agentforce platform. Execution risk remains real — some analysts rightly point to decelerating cRPO metrics — but the underlying story of a company reinventing itself for the age of agentic AI remains intact.
Technicals: Stabilized, Not Reversed
From a chart perspective, the picture is mixed but no longer alarming. The RSI-14 sits at 48.9, squarely in neutral territory — neither oversold nor overbought. The stock has recovered 11.64% from its 52-week low of €129.22, suggesting that the worst of the panic selling may be behind it.
Salesforce at a turning point? This analysis reveals what investors need to know now.
Still, Salesforce remains 2.42% below its 50-day moving average of €147.84 and roughly 18% below the 200-day average. A single strong session does not constitute a trend reversal. The market is waiting for a catalyst.
What Comes Next
That catalyst could arrive within days. The Federal Reserve’s rate decision on July 28-29 will set the valuation parameters for high-growth tech names. Immediately afterward, Microsoft and Meta report on July 29, followed by Amazon and Apple on July 30. Their commentary on enterprise AI spending will likely determine whether Salesforce can reclaim the €147.84 level.
A failure to break through risks a retest of the 52-week low at €129.22. A successful breakout, by contrast, would give technical backing to the analyst consensus target of €212.48 for the first time in months.
The VA deal proves that the agentic AI narrative has substance. Whether the broader market agrees will become clear in the next several trading sessions — at the Fed’s rate decision and in the earnings calls of the tech giants that set the tone for enterprise AI budgets.
Ad
Salesforce Stock: New Analysis - 26 July
Fresh Salesforce information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
